Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of October 19, 2026, RGEN trades at $175.51 with a market cap of $11.14B and a P/E ratio of 230.18. RGEN moved -4.75% today. Year to date, RGEN is +7.05%; over the trailing twelve months it is +13.50%. Its 52-week range spans $100.99 to $198.87. Analyst consensus is strong buy with an average price target of $196.67. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Repligen completes acquisition of BioLife Solutions in cash-and-stock deal: Repligen completed its acquisition of BioLife Solutions. BioLife holders received $11.25 per share in cash plus 0.1442 Repligen shares, and Repligen plans to outline the deal’s expected effect on its 2026 financial outlook on its Q3 2026 earnings call.
| Metric | Value |
|---|---|
| Price | $175.51 |
| Market Cap | $11.14B |
| P/E Ratio | 230.18 |
| EPS | $0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $198.87 |
| 52-Week Low | $100.99 |
| Volume | 989.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $785.10M |
| Net Income | $41.54M |
| Gross Margin | 53.84% |
9 analysts cover RGEN: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $196.67.